₹689.8
▲ +8.18 +1.20%
As of 28 Jul 2026 · delayed
NSE Listed · Healthcare
Nephrocare Health Serv Limited (NEPHROPLUS)
Volume: 1,81,380Avg Vol 1W: 2,25,186Avg Vol 1M: 1,91,43952W Range:₹446₹769.75
Key Ratios
Checked 9h agoMarket Cap₹6,937 Cr
Current Price₹689.8
Previous Close₹681.62
High / Low (52w)₹769.75 / ₹446
Volume1,81,380
Avg Vol (1W)2,25,186
Avg Vol (1M)1,91,439
Stock P/E92.59
Book Value₹111.03
Dividend Yield0%
ROE6.88%
ROA5.22%
Revenue (TTM)—
Revenue Growth33.5%
Profit Margin7.69%
Total Debt₹96 Cr
Shares Outstanding10 Cr
Face Value₹10
EPS (TTM)₹7.45
P/B6.21
Debt / Equity0.07
50 DMA₹665.79
200 DMA—
Day change+1.20%
Price Chart
₹689.8▲ 46.38% · 1Y
2025-12-172026-07-28
20-day avg volume: 1.9L shares
Pros
- Company is almost debt-free.
Cons
- Revenue fell 84% YoY.
- Stock trades at a high P/E of 93.
Quarterly Results
| Metric | Dec 2024 | Mar 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | ₹197 Cr | ₹219 Cr | ₹246 Cr | ₹260 Cr | ₹266 Cr |
| EBITDA | ₹31 Cr | ₹36 Cr | ₹44 Cr | ₹42 Cr | ₹39 Cr |
| Net Profit | ₹20 Cr | ₹25 Cr | ₹-9 Cr | ₹32 Cr | ₹30 Cr |
| EPS | — | — | — | — | — |
Profit & Loss (Annual)
| Metric | Mar 2024 | Dec 2024 | Mar 2025 | Mar 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹575 Cr | ₹138 Cr | ₹145 Cr | ₹770 Cr | ₹156 Cr | ₹161 Cr | ₹164 Cr | ₹1,023 Cr |
| EBITDA | ₹53 Cr | ₹14 Cr | ₹11 Cr | ₹108 Cr | ₹10 Cr | ₹13 Cr | ₹12 Cr | ₹161 Cr |
| Net Profit | ₹35 Cr | ₹8 Cr | ₹6 Cr | ₹67 Cr | ₹-32 Cr | ₹8 Cr | ₹11 Cr | ₹77 Cr |
| EPS | 4.4 | — | — | 8.01 | — | — | — | 8.1 |
Balance Sheet
| Metric | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Total Assets | ₹428 Cr | ₹571 Cr | ₹666 Cr | ₹806 Cr | ₹996 Cr | ₹1,471 Cr |
| Total Liabilities | ₹169 Cr | ₹175 Cr | ₹278 Cr | ₹392 Cr | ₹412 Cr | ₹354 Cr |
| Equity | ₹259 Cr | ₹396 Cr | ₹389 Cr | ₹414 Cr | ₹584 Cr | ₹1,116 Cr |
| Total Debt | — | — | — | — | — | — |
Cash Flow
| Metric | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Operating | ₹18 Cr | ₹19 Cr | ₹7 Cr | ₹80 Cr | ₹136 Cr | ₹260 Cr |
| Investing | ₹-61 Cr | ₹-129 Cr | ₹-78 Cr | ₹-51 Cr | ₹-125 Cr | ₹-410 Cr |
| Financing | ₹36 Cr | ₹121 Cr | ₹60 Cr | ₹27 Cr | ₹54 Cr | ₹157 Cr |
| Free Cash Flow | ₹18 Cr | ₹19 Cr | ₹7 Cr | ₹80 Cr | ₹136 Cr | ₹260 Cr |
Shareholding
Promoter 63.85% Institutions 17.83% Public 18.32%
Efficiency & Working Capital
ROCE13.2%
Interest Coverage2.6
Dividend Payout—
Debtor Days129 d
Inventory Days13 d
Payable Days55 d
Cash Conversion Cycle87 d
Working Capital Days142 d
Shareholding Details
As of 2026-06-30
Promoter63.9%
FII8.8%
DII9%
Institutions17.8%
Public18.3%
Promoter Pledge0%
No. of Shareholders44,091
Shareholding Pattern
Quarterly — figures in %. Latest 5 quarters.
| Period | Jul 2025 | Jul 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|
| Promoters | 79.1% | 79.1% | 63.9% | 63.9% | 63.9% |
| FIIs | 0% | 0% | 9.3% | 9.9% | 8.8% |
| DIIs | 20.9% | 0% | 8.1% | 8.6% | 9% |
| Public | 0% | 20.9% | 18.7% | 17.6% | 18.3% |
| Promoter Pledge | 0% | 0% | 0% | 0% | 0% |
| No. of Shareholders | 65 | 65 | 67,416 | 43,409 | 44,091 |
Returns History (ROE / ROCE / ROA)
| Period | ROE | ROCE | ROA | P/E |
|---|---|---|---|---|
| 202503 | — | — | — | — |
Major Shareholders (>1%)
| Name | Category | Stake | Shares |
|---|---|---|---|
| Edoras Investment Holdings Pte Ltd | Shareholding of Promoter and Promoter Group | 28.3% | 2.84 Cr |
| Vikram Vuppala | Shareholding of Promoter and Promoter Group | 9.8% | 98,24,227 |
| Bessemer Venture Partners Trust | Shareholding of Promoter and Promoter Group | 8.7% | 86,85,150 |
| Investcorp India Investments Holding Limited | Public Shareholding | 6.3% | 63,08,976 |
| Healthcare Parent Limited | Shareholding of Promoter and Promoter Group | 5.8% | 58,24,260 |
| Polar Capital Funds Plc - Healthcare Opportunities | Public Shareholding | 5.8% | 57,80,962 |
| Investcorp Private Equity Fund Ii | Shareholding of Promoter and Promoter Group | 5.3% | 53,33,510 |
| International Finance Corporation | Public Shareholding | 3.1% | 30,89,662 |
| Quadria Capital India Fund Iii | Shareholding of Promoter and Promoter Group | 1.9% | 18,82,080 |
| The Prudential Assurance Company Limited | Public Shareholding | 1.9% | 18,78,420 |
| Viraaj Family Trust (trustee Ms. Manju Vuppala ) | Shareholding of Promoter and Promoter Group | 1.9% | 18,57,150 |
| Manvi Family Trust (trustee Mr. Vikram Vuppala) | Shareholding of Promoter and Promoter Group | 1.8% | 17,72,265 |
| 360 One Special Opportunities Fund - Series 9 | Public Shareholding | 1.3% | 13,09,067 |
| Sbi Healthcare Opportunities Fund | Public Shareholding | 1.2% | 11,92,334 |
| Investcorp India Alternatives Fund - Investcorp Gr | Shareholding of Promoter and Promoter Group | 0.5% | 4,74,630 |
| Pankaja Gatuku | Shareholding of Promoter and Promoter Group | 0% | 22,665 |
| Healthcare Private Equity Limited | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Quadria Capital Fund Iii Holdings Pte. Ltd | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Anunta Technology Management Services Limited | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Applied Energy Technologies Private Limited (formerly Known As Applied Solar Technologies (india)) | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Bessemer India Capital Holdings Ii Limited | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Intergrow Brands Private Limited | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Paris De Salon Private Limited | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Starlet Projects Private Limited | Shareholding of Promoter and Promoter Group | 0% | 0 |
| V-ensure Pharma Technologies Private Limited | Shareholding of Promoter and Promoter Group | 0% | 0 |
Board of Directors
| Name | Designation | Year |
|---|---|---|
| Vikram Vuppala | Chairman & Managing Director | 2025 |
| Vishal Vijay Gupta | Non Executive Director / Nominee | 2025 |
| Gaurav Sharma | Non Executive Director / Nominee | 2025 |
| SUNIL KUMAR THAKUR | Non Executive Director / Nominee | 2025 |
| Om Prakash Manchanda | Independent Director | 2025 |
| HEMANT SULTANIA | Independent Director | 2025 |
| Annette Bent Ingrid Kumlien | Independent Director | 2025 |
| Ajay Bakslii | Independent Director | 2025 |
| Kishore Kathri | Company Sec. & Compli. Officer | 2025 |
Capital Structure (₹ Cr)
| Year | Face Value | Authorised | Issued | Paid-up |
|---|---|---|---|---|
| 2026 | ₹2 | 25 | 20 | 20 |
Corporate Actions
| Type | Date | Value | Remark |
|---|---|---|---|
| forthcoming | 2026-08-11 | Board Meetings | — |
Substantial Acquisitions (SAST)
1 disclosure(s)
Market19/12/2025 · 2,14,331
Company Information
🌐 www.nephroplus.com ↗
📍 5th Flr D Block iLabs Centre, Plot 18 Software Units Sy.#.64, Hyderabad, Telangana, 500081
Technical AnalysisPremium
Technical analysis (Premium)
Log in to see RSI, MACD, moving averages, oscillators and pivot levels for this stock.
More stocks
Neelam Linens and Garments (India) Ltd.Nelcast LimitedNELCO Ltd.Neochem Bio Solutions Ltd.Neogen Chemicals LimitedNephro Care India LimitedNeptune Petrochemicals LimitedNesco Ltd.Nestle India LimitedNetweb Technologies India Ltd.Network 18 Media & Investments Ltd.Neueon Corporation Ltd.All “N” stocks →
Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search